Browse by author
Lookup NU author(s): Dr Martin Prince,
Dr Mark Hudson,
Professor Chris Day,
Emeritus Professor Oliver James,
Professor David Jones
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Controlled trials have suggested that opiate antagonist therapy may be effective for the treatment of the symptoms of cholestasis. The oral opiate antagonist naltrexone in particular has started to enter into routine clinical use for amelioration of cholestatic itch. Attention regarding the side effects of opiate antagonist therapy has, to date, largely focused on an opiate withdrawal-type reaction (which can be controlled effectively by titrated therapy introduction regimens). Here we describe 3 cases of a further clinically important side effect, loss of control of pain resulting from other pathologies, which in each case necessitated the withdrawal of hitherto clinically effective opiate antagonist therapy. Of the 14 patients treated by our unit with opiate antagonist agents for the control of cholestatic symptoms, 13 (93%) showed resolution of, or significant improvement in, symptoms. Of the 13 patients showing a clinical response, 7 (54%) subsequently had to discontinue therapy because of side effects (including the 3 patients with uncontrolled pain). It is our experience that in the routine clinical setting, opiate antagonists are highly effective for the treatment of cholestatic symptoms. In practice, however, their usefulness is limited by their side-effect profile.
Author(s): McRae CA, Prince MI, Hudson M, Day CP, James OFW, Jones DEJ
Publication type: Article
Publication status: Published
ISSN (print): 0016-5085
ISSN (electronic): 1528-0012
Publisher: WB Saunders Co.
PubMed id: 12891561
Altmetrics provided by Altmetric